Roy Buchanan
Stock Analyst at JMP Securities
(4.39)
# 369
Out of 4,981 analysts
69
Total ratings
49.25%
Success rate
24.83%
Average return
Main Sectors:
Stocks Rated by Roy Buchanan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DVAX Dynavax Technologies | Reiterates: Market Outperform | $32 | $9.24 | +246.32% | 8 | Aug 22, 2025 | |
| ENTA Enanta Pharmaceuticals | Maintains: Market Outperform | $24 → $25 | $7.79 | +220.92% | 15 | Aug 12, 2025 | |
| CDTX Cidara Therapeutics | Maintains: Market Outperform | $59 → $66 | $65.50 | +0.76% | 7 | Aug 8, 2025 | |
| PYPD PolyPid | Maintains: Market Outperform | $16 → $14 | $3.40 | +311.76% | 2 | Jun 17, 2025 | |
| CVAC CureVac | Reiterates: Market Outperform | $10 | $5.35 | +87.09% | 9 | May 28, 2025 | |
| ANTX AN2 Therapeutics | Maintains: Market Outperform | $5 → $2 | $1.25 | +60.00% | 9 | May 5, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Market Outperform | $18 | $2.28 | +691.21% | 3 | Mar 14, 2025 | |
| TPG TPG Inc. | Reiterates: Market Perform | n/a | $61.80 | - | 1 | Feb 13, 2025 | |
| ESPR Esperion Therapeutics | Reiterates: Market Outperform | $7 → $4 | $2.81 | +42.60% | 3 | Feb 11, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Market Outperform | $23 → $14 | $1.30 | +981.08% | 1 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $33 | $86.54 | -61.87% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $4 → $5 | $4.45 | +12.49% | 5 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $443 → $448 | $753.39 | -40.54% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $14 → $16 | $12.66 | +26.38% | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.90 | - | 2 | Feb 16, 2023 |
Dynavax Technologies
Aug 22, 2025
Reiterates: Market Outperform
Price Target: $32
Current: $9.24
Upside: +246.32%
Enanta Pharmaceuticals
Aug 12, 2025
Maintains: Market Outperform
Price Target: $24 → $25
Current: $7.79
Upside: +220.92%
Cidara Therapeutics
Aug 8, 2025
Maintains: Market Outperform
Price Target: $59 → $66
Current: $65.50
Upside: +0.76%
PolyPid
Jun 17, 2025
Maintains: Market Outperform
Price Target: $16 → $14
Current: $3.40
Upside: +311.76%
CureVac
May 28, 2025
Reiterates: Market Outperform
Price Target: $10
Current: $5.35
Upside: +87.09%
AN2 Therapeutics
May 5, 2025
Maintains: Market Outperform
Price Target: $5 → $2
Current: $1.25
Upside: +60.00%
Inovio Pharmaceuticals
Mar 14, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $2.28
Upside: +691.21%
TPG Inc.
Feb 13, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $61.80
Upside: -
Esperion Therapeutics
Feb 11, 2025
Reiterates: Market Outperform
Price Target: $7 → $4
Current: $2.81
Upside: +42.60%
Ironwood Pharmaceuticals
Jan 30, 2025
Maintains: Market Outperform
Price Target: $23 → $14
Current: $1.30
Upside: +981.08%
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $86.54
Upside: -61.87%
Aug 2, 2024
Maintains: Market Outperform
Price Target: $4 → $5
Current: $4.45
Upside: +12.49%
Mar 3, 2023
Maintains: Market Outperform
Price Target: $443 → $448
Current: $753.39
Upside: -40.54%
Mar 1, 2023
Maintains: Market Perform
Price Target: $14 → $16
Current: $12.66
Upside: +26.38%
Feb 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.90
Upside: -